MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance
Document Type
Journal ArticlePublication Date
2017-10-26Keywords
Cancer therapeutic resistanceCancer Biology
Cellular and Molecular Physiology
Female Urogenital Diseases and Pregnancy Complications
Neoplasms
Metadata
Show full item recordAbstract
Understanding the mechanisms of platinum compound resistance, including cisplatin resistance, has important implications for improving cancer treatments. Previous studies identified a potential role for mitogen-activated protein kinase phosphatase-1 (MKP-1) in cisplatin resistance. This work focuses on the regulation of poly(ADP-ribose) polymerase-1 (PARP-1) expression by MKP-1. We found that MKP-1 overexpression stimulates PARP-1 and poly(ADP-ribose) (PAR) protein expression and cisplatin resistance while its downregulation suppresses PARP-1 and PAR protein expression and cisplatin resistance. Silencing MKP-1 promoted PARP-1 ubiquitination, which decreased PARP-1 protein levels. We also found that silencing c-Jun N-terminal kinase 1/2 (JNK1/2) decreased PARP-1 ubiquitination while increasing total PARP-1 protein levels. Furthermore, we showed that acquired cisplatin-resistant ovarian cancer cells expressed high levels of MKP-1 and PARP-1 proteins, and that silencing MKP-1 or PARP-1 increased cisplatin sensitivity in resistant cells. Notably, the pharmacologic inhibition of PARP activity restored cisplatin sensitivity in MKP-1 overexpressing cells. Thus, this work indicates that suppression of JNK1/2 activity by MKP-1 maintains PARP-1 levels and suggests that MKP-1-mediated cisplatin resistance can be bypassed by PARP-1 inhibition.Source
Oncogene. 2017 Oct 26;36(43):5939-5947. doi: 10.1038/onc.2017.197. Epub 2017 Jun 26. Link to article on publisher's site
DOI
10.1038/onc.2017.197Permanent Link to this Item
http://hdl.handle.net/20.500.14038/40476PubMed ID
28650468Related Resources
ae974a485f413a2113503eed53cd6c53
10.1038/onc.2017.197